Neurocrine and Voyager Collaborate to Develop and Commercialize VY-AADC & VY-FXN01 for Parkinson’s & Friedreich’s Ataxia Disease
Neurocrine and Voyager Collaborate to Develop and Commercialize VY-AADC & VY-FXN01 for Parkinson’s & Friedreich’s Ataxia Disease
Shots:
- Voyager to receive $165M upfront including $115M in cash, $50M equity investment at $11.96/share and $1.7B milestones for its four gene therapy programs including VY-AADC & VY-FXN01. Additionally, Neurocrine to fund the two undisclosed gene therapy programs and Voyager to receive milestone and royalties on its WW sales
- Neurocrine to fund P-II/III & P-I for VY-AADC (RESTORE-1) study & VY-FXN01 respectively. Post P-II &P-I completion, Voyager has an option for co-commercialization with 50/50 & 60/40 cost-profit (Neurocrine/ Voyager) sharing in the US for VY-AADC & VY-FXN01 respectively. In case of non-exercising of an option, Vogayer will grant WW & US rights of VY-AADC & VY-FXN01 respectively to Neurocrine for milestone and royalties
- Voyager’s VY-AADC & VY-FXN01 are gene therapy products targeted for direct delivery of AADC gene in neurons & for controlling FXN protein levels respectively
Click here to read full press release/ article | Ref: Globe NewsWire | Image: Market Exclusive